


| Key | % Net Assets |
|---|---|
| 6.4% | |
| 5.8% | |
| 5.5% | |
| 4.6% | |
| 77.7% |
| Name | % Net Assets |
|---|---|
| GlaxoSmithKline | 6.4% |
| Royal Dutch Shell | 5.8% |
| BP | 5.5% |
| HSBC | 4.6% |
| UBM | 4.1% |
| Tyman plc | 3.8% |
| Reed Elsevier | 3.7% |
| Vodafone | 3.3% |
| Henry Boot | 3.1% |
| FirstGroup | 2.9% |
| Key | % Net Assets |
|---|---|
| 19.50% | |
| 19.30% | |
| 16.20% | |
| 15.10% | |
| 11.70% |
| Date | 19-Aug-2025 |
|---|---|
| NAV | 8,777.38p |
| Currency | GBP |
| Change | 64.05p |
| % | 0.74% |
| YTD change | 471.23p |
| YTD % | 5.67% |
| Fund Inception | 20/06/2002 |
|---|---|
| Fund Manager | Matthew Tillett |
| TER | 1.43 (31-Aug-2013) |
| Minimum Investment | |
|---|---|
| Initial | £500 |
| Additional | £500 |
| Savings | £50 |
| Charges | |
|---|---|
| Initial | 4.00% |
| Annual Mang't | 1.25% |
| Exit | n/a |
| Name | % |
|---|---|
| Standard deviation | 0.02 |
| Sharpe ratio | 0.06 |
You are here: research